About Xenon Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: CA
- Website: https://www.xenon-pharma.com/
Frequently Asked Questions
What is the 52-week range for XENE?
The 52-week high is $72.66 and the 52-week low is $36.07.
What is the P/E ratio for XENE?
The P/E ratio data is currently unavailable.
What is the dividend yield for XENE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -43.98%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -867.29%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.09.
Analyst Recommendation Trends
Wall Street analyst consensus for XENE over the last few months:
Latest XENE News
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were a
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
CEO Ian Mortimer and CFO Thomas Kelly purchased 45,000 shares of XENE in the open market.
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says
Xenon Pharmaceuticals' (XENE) safety data has raised investor concerns about a potential Food and Dr
Ian Mortimer Receives the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, as the recipient of the 2026 Bloom Burton Award. 2026 Bloom Burton Award Winner Ian Mortimer, President and Chief Executive Officer of Xenon PharmaceuticalsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/6420/316465_7cc4242184cef922_001full.jpgIn the past..
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.Sherry Aulin is a finance executive with more than
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability. Speaking at the 2026 TD Cowen Neuropsychiat
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) advanced its epilepsy program while encountering a new obstacle to expansion. On September 17, it submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner in focal seizures, which originate in a specific area of the brain. The same announcement disclosed a voluntary pause in new enrollment […]
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate
Xenon Pharmaceuticals Inc. stock: Azetukalnerâs focal seizure program could drive first revenues pending FDA approval. Click for this XENE update.
Xenon stock lost 30%, but the FDA story is more complicated
Wall Street reacts as the drugmaker’s experimental medication hits a roadblock.
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET Details a
Company News for Sep 21, 2026
Companies in The News Are: STLD,XENE,AMD,TXN
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment
Key Stats for Xenon Pharmaceuticals StockPrice change for Xenon Pharmaceuticals stock: -31%$XENE Stock Price as of Sep. 19: $4052-Week High: $73$XENE Stock Price Target: $78What Happened?Xenon Pharmaceuticals (XENE) stock is under pressure after the company paused enrollment in its Phase 3 psychiatry studies for major depressive disorder and bipolar disorder.
Triple Witching Whipsaws Wall Street While Crypto Stocks Steal the Show
Friday's quarterly options expiry turned Wall Street into a roller coaster, with the ten-year yield back at 5% and crypto stocks surging as bitcoin reclaimed $80,000. Netflix drew a rare sell rating, two steelmakers stumbled, and the White House announced an "AI Force" over the weekend.
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data
Earlier this month, Xenon Pharmaceuticals submitted a New Drug Application to the US FDA for azetukalner in focal seizures, supported by two randomized, double-blind, placebo-controlled trials showing statistically significant seizure reduction and a generally consistent safety profile across more than 1,500 patient-years of exposure. On the same day, the company voluntarily paused new enrollment in its Phase 3 major depressive disorder and bipolar depression studies due to neuropsychiatric...
This Biotech Surged 50% On Positive Data In March. Now, It's Completely Gone.
Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a 10-month low.
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial
Xenon Pharmaceuticals stock sinks as the company halts enrollment of new patients in a key trial. Here’s how you should play XENE shares at current levels.
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’
Sector Update: Healthcare Stocks Decline Friday Afternoon
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index decreasing 0.5% and th
Let's take a look at the stocks that are in motion in today's session.
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause
Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company voluntarily halted new enrollment in major depressive disorder and bipolar depression studies. The events were consistent with azetukalner's known safety profile, Xenon said, but had not...
Xenon Pharmaceuticals' Azetukalner Retains Core Epilepsy Value, RBC Capital Markets Says
Xenon Pharmaceuticals' (XENE) enrollment pause in an ongoing phase 3 trial of azetukalner adds risk
Xenon Stock Reaction Is Overblown: Analyst
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures. Simultaneously, the neuroscience-focused biopharmaceutical company announced a voluntary pause on new patient enrollment in its ongoing depression clinical studies following reports of neuropsychiatric adverse events. Positive Data Drives FDA Submission The regulatory filing relies on clinical data from the Phase 2b X
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.
Friday's session: gap up and gap down stocks
Let's have a look at the gap up and gap down stocks in today's session.
Cigna downgraded, Humana upgraded: Wall Street's top analyst calls
Cigna downgraded, Humana upgraded: Wall Street's top analyst calls
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular session. The market value of their outstanding shares is at $1.0 million. SkyAI (NASDAQ:SKYA) stock rose 20.43% to
Stay updated with the stocks that are on the move in today's pre-market session.
Wondering what's happening in Friday's pre-market session? Find an overview in this article.
Xenon: The Psychiatry Pause Matters More Than You Think (Rating Downgrade)
Xenon is downgraded to Hold after pausing azetukalner trials in MDD and bipolar depression due to neuropsychiatric adverse events. Read more on XENE stock here.
Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge
U.S. stocks fell Friday as weak industrial data weighed; Dow slid 0.45%, materials lagged, energy rose, and European shares declined.
Premarket movers: Xenon sinks on trial pause, Netflix hit by downgrade
Investing.com - U.S. stock futures edged broadly higher on Friday, following a rally in stocks in the wake of the Federal Reserve’s interest rate hike on Wednesday.
Xenon shares fall following depression trial pause
The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.
Update: Xenon Shares Fall on Pause in Enrollment for Depression Studies
(Updates with the latest share moves and details in the headline, first and second paragraph.) Xe
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $81 to $70.
US Stocks Mixed; Industrial Production Unchanged In August
U.S. stocks mixed Friday: Nasdaq and S&P 500 edged higher, Dow slipped. Oil rose; industrial production was flat, while GIPR and IMCC surged.
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $71 to $55.
This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Analysts downgraded Magna, Franklin BSP, and more revising price targets for several.
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.
Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $64
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $69 to $64.
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. Alaunos Therapeutics (NASDAQ:TCRT) shares increased
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold, Lowers Price Target to $46
Deutsche Bank analyst David Hoang downgrades Xenon Pharmaceuticals (NASDAQ:XENE) from Buy to Hold and lowers the price target from $90 to $46.
Market-Moving News for September 18th
TCRT: 69% | Alaunos Therapeutics On Thursday Filed Patent Application "Identification Of Neoantigen-Reactive T Cell Receptors" MEDS: 24% | DataMeds AI Settles Litigation Related To Outstanding Debt And
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $78 to $60.
Baird Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $90
Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $97 to $90.
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.
Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why
Xenon Pharmaceuticals shares fell 25% after hours after pausing new patient enrollment in ongoing psychiatry clinical studies.
Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04
These stocks are moving in today's after hours session
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in MDD completed with approximately 360 total patients; topline data readout expected Q1 2027 The Company has voluntarily initiated a temporary pause of enrollment of new patients in ongoing psychiatry studies; patients currently enrolled in the ongoing studies remain activeConferenc
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock increased by
Xenon Pharmaceuticals Announces Voluntarily Initiated A Temporary Pause Of Enrollment Of New Patients In Ongoing Psychiatry Studies Following Neuropsychiatric Adverse Events; Patients Currently Enrolled In The Ongoing Studies Remain Active
In addition, the Company announced today that it has implemented a voluntary pause on enrollment for new patients in its ongoing clinical studies in major depressive disorder (MDD) and bipolar depression (BPD),
Xenon Pharmaceuticals Says X-NOVA2 Enrollment Reaches ~80% Of Its Initial Target Of 450 Patients; Topline Data Readout Expected Q1 2027
X-NOVA2 enrollment has reached approximately 80% of its initial target of 450 patients, which is sufficiently powered to demonstrate a clinically meaningful change in the study’s primary endpoint of HAM-D17. The Company
Xenon Pharmaceuticals Submits NDA For Azetukalner In Focal Seizures To FDA
New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectivelyEnrollment in X-NOVA2 study in
Xenon Pharmaceuticals: Epilepsy Got It To $59; Depression Has To Take It From Here
Xenonâs Phase 3 azetukalner cut focal seizures by 53%, and FDA filing nears. Click for more on XENE stock.
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care
On August 26, Xenon Pharmaceuticals (NASDAQ:XENE) announced that it will deliver six data presentations at the 16th European Epilepsy Congress in Athens, Greece, running September 5 through 9. The headline slot is an oral presentation of topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, alongside two posters covering patients […]
Xenon to Present at Wells Fargo Healthcare Conference
VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: Wells Fargo Healthcare Conference, Boston, MAFireside Chat: Wednesday, September 9, 11:00–11:30 am ET Details about the presentation, inc
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | MORTIMER IAN | +30,000 | $37.38 | $1,121,400 |
| 2026-09-30 | Kelly Thomas Patrick | +15,000 | $37.316 | $559,740 |
| 2026-09-01 | Svoronos Dawn | -5,144 | - | - |
| 2026-09-01 | Svoronos Dawn | +5,144 | $8.15 | $41,924 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | -700 | $60.9766 | $42,684 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | -6,368 | $60.1673 | $383,145 |
| 2026-08-11 | GANNON STEVEN | -10,000 | $64.055 | $640,550 |
| 2026-06-05 | Cannon Gillian | -1,190 | $53.14 | $63,237 |
| 2026-06-05 | PATOU GARY | -1,322 | $53.14 | $70,251 |
| 2026-06-03 | Gover Justin D. | +1,593 | - | - |
| 2026-06-03 | Gover Justin D. | +10,507 | - | - |
| 2026-06-03 | GAROFALO ELIZABETH A. | +1,593 | - | - |
| 2026-06-03 | GAROFALO ELIZABETH A. | +10,507 | - | - |
| 2026-06-03 | GANNON STEVEN | +1,593 | - | - |
| 2026-06-03 | GANNON STEVEN | +10,507 | - | - |
| 2026-06-03 | Cannon Gillian | +1,593 | - | - |
| 2026-06-03 | Cannon Gillian | +10,507 | - | - |
| 2026-06-03 | Svoronos Dawn | +1,593 | - | - |
| 2026-06-03 | Svoronos Dawn | +10,507 | - | - |
| 2026-06-03 | Machado Patrick | +1,593 | - | - |
| 2026-06-03 | Machado Patrick | +10,507 | - | - |
| 2026-06-03 | PATOU GARY | +1,593 | - | - |
| 2026-06-03 | PATOU GARY | +10,507 | - | - |
| 2026-06-01 | Gover Justin D. | -2,645 | - | - |
| 2026-06-01 | Gover Justin D. | +2,645 | - | - |
| 2026-06-01 | GAROFALO ELIZABETH A. | -2,645 | - | - |
| 2026-06-01 | GAROFALO ELIZABETH A. | +2,645 | - | - |
| 2026-06-01 | GANNON STEVEN | -2,645 | - | - |
| 2026-06-01 | GANNON STEVEN | -1,416 | $53.41 | $75,629 |
| 2026-06-01 | GANNON STEVEN | +2,645 | - | - |
| 2026-06-01 | Cannon Gillian | -2,645 | - | - |
| 2026-06-01 | Cannon Gillian | +2,645 | - | - |
| 2026-06-01 | Svoronos Dawn | -2,645 | - | - |
| 2026-06-01 | Svoronos Dawn | -1,416 | $53.41 | $75,629 |
| 2026-06-01 | Svoronos Dawn | +2,645 | - | - |
| 2026-06-01 | Machado Patrick | -2,645 | - | - |
| 2026-06-01 | Machado Patrick | +2,645 | - | - |
| 2026-06-01 | PATOU GARY | -2,645 | - | - |
| 2026-06-01 | PATOU GARY | +2,645 | - | - |
| 2026-05-12 | GANNON STEVEN | -3,500 | - | - |
| 2026-05-12 | GANNON STEVEN | +3,500 | $7.38 | $25,830 |
| 2026-03-13 | KENNEY CHRISTOPHER JOHN | -1,410 | $55.225 | $77,867 |
| 2026-03-13 | DiFabio Andrea | -1,342 | $55.225 | $74,112 |
| 2026-03-13 | MORTIMER IAN | -7,308 | $55.225 | $403,584 |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN | -3,750 | - | - |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN | +3,750 | - | - |
| 2026-03-12 | DiFabio Andrea | -3,750 | - | - |
| 2026-03-12 | DiFabio Andrea | +3,750 | - | - |
| 2026-03-12 | MORTIMER IAN | -12,500 | - | - |
| 2026-03-12 | MORTIMER IAN | +12,500 | - | - |
| 2026-03-10 | KENNEY CHRISTOPHER JOHN | -2,771 | $60.108 | $166,559 |
| 2026-03-10 | DiFabio Andrea | -2,607 | $60.108 | $156,702 |
| 2026-03-10 | MORTIMER IAN | -11,269 | $60.108 | $677,357 |
| 2026-03-09 | KENNEY CHRISTOPHER JOHN | -7,500 | - | - |
| 2026-03-09 | KENNEY CHRISTOPHER JOHN | +7,500 | - | - |
| 2026-03-09 | KENNEY CHRISTOPHER JOHN | +7,500 | - | - |
| 2026-03-09 | DiFabio Andrea | -7,500 | - | - |
| 2026-03-09 | DiFabio Andrea | +7,500 | - | - |
| 2026-03-09 | DiFabio Andrea | +7,500 | - | - |
| 2026-03-09 | MORTIMER IAN | -20,000 | - | - |
| 2026-03-09 | MORTIMER IAN | +20,000 | - | - |
| 2026-03-09 | MORTIMER IAN | -65,000 | - | - |
| 2026-03-09 | MORTIMER IAN | -105,000 | - | - |
| 2026-03-09 | MORTIMER IAN | -25,000 | - | - |
| 2026-03-09 | MORTIMER IAN | -75,000 | - | - |
| 2026-03-09 | MORTIMER IAN | +20,000 | - | - |
| 2026-03-09 | MORTIMER IAN | -65,000 | $62.06 | $4,033,900 |
| 2026-03-09 | MORTIMER IAN | +65,000 | $9.44 | $613,600 |
| 2026-03-09 | MORTIMER IAN | -61,652 | $60.08 | $3,704,052 |
| 2026-03-09 | MORTIMER IAN | -43,348 | $59.26 | $2,568,802 |
| 2026-03-09 | MORTIMER IAN | +105,000 | $4.75 | $498,750 |
| 2026-03-09 | MORTIMER IAN | -2,449 | $61.26 | $150,026 |
| 2026-03-09 | MORTIMER IAN | -10,072 | $60.47 | $609,054 |
| 2026-03-09 | MORTIMER IAN | -12,479 | $59.5 | $742,501 |
| 2026-03-09 | MORTIMER IAN | +25,000 | $3.1 | $77,500 |
| 2026-03-09 | MORTIMER IAN | -21,515 | $60.49 | $1,301,442 |
| 2026-03-09 | MORTIMER IAN | -31,694 | $59.88 | $1,897,837 |
| 2026-03-09 | MORTIMER IAN | -21,791 | $58.81 | $1,281,529 |
| 2026-03-09 | MORTIMER IAN | +75,000 | $8.4 | $630,000 |
| 2026-01-09 | KENNEY CHRISTOPHER JOHN | +20,000 | - | - |
| 2026-01-09 | KENNEY CHRISTOPHER JOHN | +100,000 | - | - |
| 2026-01-09 | Cline Darren S | +20,000 | - | - |
| 2026-01-09 | Cline Darren S | +40,000 | - | - |
| 2026-01-09 | DiFabio Andrea | +15,000 | - | - |
| 2026-01-09 | DiFabio Andrea | +80,000 | - | - |
| 2026-01-09 | MORTIMER IAN | +65,000 | - | - |
| 2026-01-09 | MORTIMER IAN | +350,000 | - | - |
| 2026-01-02 | MORTIMER IAN | -40,000 | - | - |
| 2026-01-02 | MORTIMER IAN | -2,062 | $44.93 | $92,646 |
| 2026-01-02 | MORTIMER IAN | -37,938 | $44.4 | $1,684,447 |
| 2026-01-02 | MORTIMER IAN | +40,000 | $7.49 | $299,600 |
| 2025-12-08 | MORTIMER IAN | -2,010 | $46.32 | $93,103 |
| 2025-12-08 | MORTIMER IAN | -8,820 | $45.59 | $402,104 |
| 2025-12-05 | MORTIMER IAN | -14,375 | $45.03 | $647,306 |
| 2025-11-28 | MORTIMER IAN | -97 | $45.01 | $4,366 |
| 2025-10-15 | Kelly Thomas Patrick | +30,000 | - | - |
| 2025-10-15 | Kelly Thomas Patrick | +225,000 | - | - |